The subchronic toxicity of dibromoacetonitrile (DBAN), a disinfection by-product in drinking water, was studied in the rat. Male (180±18 g) and female (152±9 g) Sprague–Dawley rats (10 animals per group) were fed DBAN in organic-free distilled water at concentrations of 0.1, 1, 10 and 100 ppm for 13 weeks. Control rats received organic-free distilled water only. Water intakes in the highest dose males and females were reduced by 25 and 32% as compared to the controls, respectively ( P<0.05), with no significant reductions in food consumption and body weight gain. The organ to body weight ratio was significantly increased in the highest-dose males and females for kidneys but not for the brain, liver, spleen, thymus and testicles. In the males, decreases were detected in serum uric acid levels at 1 and 100 ppm, and in urinary uric acid at 10 and 100 ppm. Decreased serum protein was detected in the highest-dose males and decreased serum LDH was found in the highest-dose females. Both the white blood cell and lymphocyte counts were significantly elevated in the highest-dose females. A significant increase in hepatic catalase activity was observed only in males starting at 1 ppm, and increased palmitoyl-CoA oxidase (PCO) activity was found in males and females of the highest dose group. In the males, decreased thiobarbituric acid reactive substance (TBARS) level was detected in the liver at 1.0 and 100 ppm groups, while increased TBARS was found in the serum at 100 ppm DBAN. No treatment-related changes were detected in the activities of hepatic benzyloxyresorufin O-dealkylase (BROD), pentoxyresorufin O-dealkylase (PROD) and ethoxresorufin O-deethylase (EROD), and in hepatic UDP-glucuronosyltransferase (UDPGT) and glutathione S-transferases (GST). Although DBAN is a potent inhibitor of hepatic aldehyde dehydrogenase (ALDH) and GST in vitro, there was no evidence of suppression of these enzymes in the treated animals. Mild histological changes were detected in animals receiving the highest dose, consisting of collapsed angularity, increased epithelial height in the thyroid of both sexes, and cytoplasmic vacuolation and nuclear vesiculation in the thyroid of females, increased myeloid to erythroid ratio in the bone marrow of both sexes, and cytoplasmic inclusions in the proximal tubules of male kidneys. In summary, treatment effects occurred predominantly at 100 ppm and included in both sexes: increased kidney weights, histological changes in the thyroid and bone marrow, and increased peroxisomal enzyme activities; and in males: decreased serum and urinary uric acid levels, and indication of oxidative stress. The no-observed-adverse-effect level (NOAEL) was therefore judged to be 10 ppm, equivalent to 1.11 and 1.21 mg/kg/day in the males and females, respectively.
Read full abstract